Emergent BioSolutions receives order modification worth up to $22.3 million to supply anthrax vaccine to U.S. Department of War
EBS•Emergent BioSolutions received a delivery order modification worth up to $22.3 million to supply BioThrax anthrax vaccine to the U.S. Department of War. Initial deliveries worth approximately $7.4 million begin this year, with remaining deliveries expected in 2027.
1. Order details
Emergent BioSolutions received a delivery order modification worth up to $22.3 million to supply BioThrax anthrax vaccine to the U.S. Department of War. Initial deliveries worth approximately $7.4 million begin this year, and the remaining deliveries are expected in 2027. The vaccine will support anthrax pre-exposure prevention across all branches of the U.S. military.
